全体职工：

    1月10日下午14:30，来自美国国家心脏、肺和血液研究所(NHLBI)的Neal S. Young教授，进行题为“Pathogenesis of bone marrow failure”的讲座，地点：D座5楼学术报告厅，欢迎参加。

科教处

2014年1月6日

Neal S. Young教授简介

Background

 Neal Young received a A.B. cum laude from Harvard College in 1967 and his M.D. in 1971 from the Johns Hopkins School of Medicine. He did post-graduate medical training at Massachusetts General Hospital and Barnes Hospital at Washington University in St. Louis before joining the NHLBI in 1981. He is a Master of the American College of Physicians and the recipient of more than 30 awards and honors, including most recently the 2012 Samuel J. Heyman Service to America Medal (Sammie) for Science and the Environment. Dr. Young has authored 270 original scientific and medical articles in peer reviewed journals and more than 120 reviews and book chapters. He also is author or editor of 10 medical and scientific books, including a new textbook of hematology. Dr. Young is a member of the American Society for Clinical Investigation, American Association of Physicians, American Federation for Clinical Research, American Society of Hematology, and International Society for Experimental Hematology. He is co-inventor on 7 patents concerning B19 parvovirus.

Research Interests

 Dr. Young’s research is focused on bone marrow failure—human diseases that result in a failure to produce blood cells, i.e. aplastic anemia. In severe acquired aplastic anemia, the bone marrow is entirely devoid of hematopoietic stem and progenitor cells as a result of immune-mediated destruction. The disease is incurable, but therapeutic immunosuppression through the infusion of antithymocyte globulin (ATG)—polyclonal antibodies generated in animals by inoculation with human thymocytes—has proven beneficial. Dr. Young has shown that shortened telomeres result in chromosomal instability in hematopoietic cells and precede malignant evolution in human aplastic anemia, providing insight into some potential origins of this disease.Dr. Young also focuses on the pathogenic mechanisms of the human parvovirus B19, which targets human bone marrow erythroid progenitor cells.

Selected Publications

Eltrombopag and improved hematopoiesis in refractory aplastic anemia.
Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, Parikh AR, Soto S, Biancotto A, Feng X, Lozier J, Wu CO, Young NS, Dunbar CE.    N. Engl. J. Med. 2012 Jul 5;367(1):11-9.

Horse versus rabbit antithymocyte globulin in acquired aplastic anemia.Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO, Young NS.   N. Engl. J. Med. 2011 Aug 4;365(5):430-8.

Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia.Scheinberg P, Cooper JN, Sloand EM, Wu CO, Calado RT, Young NS.    JAMA. 2010 Sep 22;304(12):1358-64. N. Engl. J. Med. 2005 Apr 7;352(14):1413-24.